-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Communicating trial results to study volunteers: what does the future hold?
Zachary P Hallinan, Kenneth A Getz
Editorial: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation